Study guide

Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

Key Takeaways Explain This Topic AI

Short stature is defined as height < -2 standard deviation scores (SDS) or < 3rd percentile; distinguishing normal variants (Constitutional Delay of Growth and Puberty vs Familial Short Stature) from pathological causes requires serial growth velocity assessment, bone age radiography (Greulich and Pyle), and mid-parental target height calculation.

Constitutional Delay of Growth and Puberty (CDGP) is characterized by delayed bone age, normal childhood growth velocity, positive family history of late puberty, and eventual achievement of normal adult height within parental target, whereas Familial Short Stature presents with normal bone age and short adult height matching mid-parental height.

Precocious puberty (<8 years in girls, <9 years in boys) is classified into Central (GnRH-dependent, elevated LH/FSH response to GnRH stimulation, treated with GnRH agonists) and Peripheral (GnRH-independent, suppressed LH/FSH, caused by McCune-Albright syndrome, CAH, or gonadal/adrenal tumors); hypothalamic hamartomas are characteristic non-neoplastic hypothalamic lesions associated with central precocity.

Turner syndrome (45,X) must be ruled out by karyotype in ANY girl presenting with unexplained short stature or pubertal delay, regardless of the presence or absence of classic dysmorphic features (webbed neck, broad chest, coarctation).

Neonatal metabolic collapse requires urgent blood gas/anion gap, glucose, lactate and ammonia testing, glucose support and metabolic-team advice. In hyperammonaemic or organic-acidaemia crises, briefly stop protein and provide glucose (often GIR 8–10 mg/kg/min); use ammonia scavengers for significant hyperammonaemia and reintroduce protein within 24–48 hours under specialist guidance.

Last updated: November 2026

Growth, Puberty, and Inborn Errors of Metabolism

Paediatric endocrinologists and general paediatricians frequently evaluate children for deviations in normal growth trajectories and pubertal timing. Concurrently, the acute presentation of an inborn error of metabolism (IEM) in a neonate or infant represents one of the most intellectually demanding and time-sensitive emergencies in medicine. Mastery of growth kinetics, bone age interpretation, hypothalamic-pituitary-gonadal (HPG) axis dynamics, and the "metabolic quartet" laboratory approach is essential for passing the European Board of Paediatrics (EBP-EAP) examination.

  • Growth Assessment and Short Stature Workup
  • Clinical Anthropometry and Growth Kinetics

Measurement Technique: Measure supine length from birth up to 2 years using a calibrated stadiometer board with a fixed headboard and movable footboard (two examiners required). Measure standing height using a wall-mounted stadiometer from 2 years of age onwards .

Normal Growth Velocity by Developmental Stage:

  • Infancy (0 to 12 months): 25 cm/year
  • Second year (12 to 24 months): 10 to 12 cm/year
  • Childhood (3 years to onset of puberty): 5 to 7 cm/year
  • Pubertal growth spurt: 8 to 12 cm/year (peaking at Tanner stage B3 in girls and G4 in boys)

Note

A sustained growth velocity of < 4.0 to 4.5 cm/year < 4.0\text{ to }4.5\text{ cm/year} < 4.0 to 4.5 cm/year during childhood is abnormal and warrants thorough evaluation, even if the child's absolute height remains temporarily within the lower normal percentiles.

Mid-Parental Target Height Calculation

The Tanner Mid-Parental Target Height estimates the child's genetic growth potential based on biological parental heights:

Target Height for Boys (cm) = Father’s Height + Mother’s Height + 13 cm 2 \text{Target Height for Boys (cm)} = \frac{\text{Father's Height} + \text{Mother's Height} + 13\text{ cm}}{2} Target Height for Boys (cm) = 2 Father’s Height + Mother’s Height + 13 cm ​ Target Height for Girls (cm) = Father’s Height − 13 cm + Mother’s Height 2 \text{Target Height for Girls (cm)} = \frac{\text{Father's Height} - 13\text{ cm} + \text{Mother's Height}}{2} Target Height for Girls (cm) = 2 Father’s Height − 13 cm + Mother’s Height ​

The target height range is defined as the target height ± 8.5 cm \pm 8.5\text{ cm} ± 8.5 cm (representing the 3rd to 97th percentile range for that family).

Bone Age Radiography

Evaluated using a single anterior-posterior radiograph of the left hand and wrist , compared against the standardized Greulich and Pyle atlas or calculated via the Tanner-Whitehouse (TW3) method.

Bone age reflects biological and skeletal maturity. Delayed bone age signifies remaining growth potential, whereas advanced bone age indicates premature epiphyseal fusion and compromised final adult height.

Differential Diagnosis of Short Stature (Height < -2 SDS or < 3rd Percentile)

Parameter Constitutional Delay of Growth and Puberty (CDGP) Familial Short Stature (FSS) Pathological / Organic Short Stature

Childhood Growth Velocity Normal ( 5 – 6 cm/year 5\text{--}6\text{ cm/year} 5 – 6 cm/year ) Normal ( 5 – 6 cm/year 5\text{--}6\text{ cm/year} 5 – 6 cm/year ) Decreased ( < 4 – 4.5 cm/year <4\text{--}4.5\text{ cm/year} < 4 – 4.5 cm/year ) or crossing centiles downward

Bone Age vs Chronological Age Markedly delayed (Bone age < < < Chronological age) Normal (Bone age ≈ \approx ≈ Chronological age) Variable; delayed in endocrine, normal in skeletal dysplasias

Family History Positive for "late bloomers" (late puberty in parents) Short parents; short stature across generations Family history of chronic disease, genetic syndromes

Pubertal Timing Delayed (starts late, prolonged growth) Normal timing Variable; often delayed or arrested

Final Adult Height Normal ; reaches mid-parental target range Short ; reaches target matching short parents Often compromised below parental target

Pathological Causes of Short Stature

Proportionate Short Stature:

Systemic Chronic Disease: Coeliac disease (mandatory screening with anti-tissue transglutaminase IgA / anti-tTG ), Inflammatory Bowel Disease (Crohn's disease may present solely as growth arrest before gastrointestinal symptoms), Chronic Kidney Disease, congenital heart disease, cystic fibrosis.

Endocrine Disorders:

Growth Hormone Deficiency (GHD): Low serum IGF-1 and IGFBP-3; failure to increase GH levels ( > 7 – 10 mcg/L >7\text{--}10\text{ mcg/L} > 7 – 10 mcg/L ) on two separate pharmacological provocation tests (clonidine, arginine, or glucagon). Pituitary MRI indicated.

Hypothyroidism: Growth arrest with preserved or increasing weight curve.

Cushing Syndrome: Growth failure accompanied by rapid central weight gain, moon facies, and purple striae.

Disproportionate Short Stature (Altered Upper-to-Lower Segment Ratio):

Skeletal Dysplasias: Achondroplasia (autosomal dominant gain-of-function mutation in FGFR3 ; rhizomelic limb shortening, macrocephaly, frontal bossing, trident hands, normal trunk length).

Genetic and Syndromic Causes:

Turner Syndrome (45,X): Mandatory karyotyping in ANY girl with unexplained short stature or pubertal delay, regardless of whether classic somatic stigmata (webbed neck, low posterior hairline, cubitus valgus, broad "shield" chest, coarctation of aorta, bicuspid aortic valve) are evident. Missing or altered sex-chromosome material causes Turner syndrome; SHOX haploinsufficiency contributes to its short stature and skeletal features.

Noonan Syndrome: Autosomal dominant ( PTPN11 mutations); short stature, webbed neck, pectus excavatum, pulmonary valve stenosis.

Prader-Willi Syndrome: Paternal deletion on 15q11-q13; infantile hypotonia, childhood hyperphagia, morbid obesity, hypogonadism.

Follow-up After Fetal Growth Restriction

Fetal growth restriction means failure to achieve growth potential; it is not identical to being statistically small for gestational age (SGA). Beyond neonatal complications, affected children need follow-up for growth and neurodevelopment. Persistent short stature and developmental difficulties may require specialist assessment. SGA birth is also associated with later cardiometabolic risk, particularly with excessive postnatal weight gain. Support adequate nutrition and proportional catch-up growth without promoting excess weight gain; monitor length/height, weight and development, and counsel about healthy activity and diet. Refer persistent short stature or developmental concerns for evaluation rather than assuming all small newborns will catch up normally.

Sources: RCOG growth-restriction guidance ; international SGA consensus .

Disorders of Puberty: Precocious and Delayed

Puberty is initiated by the reactivation of the Hypothalamic-Pituitary-Gonadal (HPG) axis , resulting in pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) by the hypothalamus, stimulating pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which drive gonadal sex steroid production.

Normal Pubertal Milestones (Tanner Staging)

Girls: The first physical sign of female puberty is thelarche (breast budding, Tanner stage B2) , occurring between 8 and 13 years of age. Menarche is a late milestone, occurring approximately 2 to 2.5 years after thelarche (average age: 12.5 years, Tanner stage B3–B4).

Boys: The first physical sign of male puberty is testicular enlargement (volume ≥ 4 mL \ge 4\text{ mL} ≥ 4 mL ) measured using a Prader orchidometer (Tanner stage G2), occurring between 9 and 14 years of age. [Early or rapidly progressive pubertal development]

  • (<8y girls, <9y boys: assess growth and Tanner stage)
  • [Girls with isolated stable B2: reassess in 4–6 months;
  • investigate B3/progression/growth acceleration or CNS signs]
  • |
  • [Ultrasensitive basal serum LH first]
  • |
  • +--------------------------+--------------------------+
  • | |
  • [Pubertal LH: supports central puberty] [Low LH despite convincing clinical signs]
  • | [GnRH/GnRHa stimulation if needed]
  • | |
  • +------------------ [Interpret with clinical course] --+
  • |
  • +--------------------------+--------------------------+
  • | |
  • [Central: HPG-axis activation] [Peripheral: gonadal/adrenal sex steroids]
  • [MRI for younger children or CNS signs] [Pelvic/testicular/adrenal imaging as indicated]
  • [No routine MRI without CNS signs in [Ovarian cyst, McCune-Albright, CAH,
  • girls 6–8 or boys 8–9: 2026 guideline] adrenal/testicular tumour]
  • | |
  • [GnRH agonist when treatment indicated] [Treat the specific cause]
  • Precocious Puberty

Defined as the appearance of secondary sexual characteristics before 8 years in girls (breast development) or 9 years in boys (testicular volume ≥ 4 mL \ge 4\text{ mL} ≥ 4 mL ).

Central Precocious Puberty (CPP / Gonadotropin-Dependent):

True premature activation of the hypothalamic GnRH pulse generator.

Biochemical Hallmark: When investigation is indicated, begin with ultrasensitive basal LH. A pubertal value supports CPP; if LH is low despite convincing progression, use GnRH/GnRHa stimulation testing (a peak above about 5 IU/L supports CPP, depending on assay/protocol). Bone age is often advanced.

Etiology:

Girls: Over 90% are idiopathic .

Boys: Intracranial causes are especially important with younger onset or neurological findings. Causes include hypothalamic hamartomas (non-neoplastic heterotopias presenting with precocious puberty and characteristic gelastic [laughing] seizures ), optic pathway gliomas (neurofibromatosis type 1), astrocytomas, hydrocephalus, or prior cranial irradiation.

Investigation: Obtain brain MRI in younger children (girls under 6, boys under 8) and at any age with CNS findings. The 2026 ESPE/ESE-co-sponsored guideline advises against routine MRI in girls 6–8 or boys 8–9 without CNS findings.

Management: Long-acting GnRH analogues (e.g., Leuprorelin, Triptorelin depot) continuously stimulate pituitary GnRH receptors, inducing receptor downregulation, suppressing gonadotropin release, halting pubertal progression, and preserving final adult height.

Peripheral Precocious Puberty (PPP / Gonadotropin-Independent):

Excess sex steroids derived from the gonads, adrenals, or exogenous exposure, with complete suppression of the HPG axis.

Biochemical Hallmark: Suppressed basal LH and FSH with flat, prepubertal response to GnRH stimulation .

Etiology:

McCune-Albright Syndrome: Triad of polyostotic fibrous dysplasia , large café-au-lait macules with irregular ("coast of Maine") borders, and autonomous recurrent ovarian cysts causing precocious vaginal bleeding. Caused by post-zygotic activating somatic mutations in the GNAS gene ( G s α G_s\alpha G s ​ α subunit).

Congenital Adrenal Hyperplasia: Excess adrenal androgens cause heterosexual precocity in girls and isosexual pseudoprecocity (pubarche, penile enlargement, but prepubertal testes < 4 mL <4\text{ mL} < 4 mL ) in boys.

Gonadal Tumors: Granulosa cell tumors of the ovary (estrogen-secreting) or Leydig cell tumors of the testis (testosterone-secreting; presents as unilateral, asymmetrical testicular enlargement ).

Testotoxicosis: Familial male-limited precocious puberty caused by activating mutations in the LH receptor gene.

Delayed Puberty

Evaluate the absence of breast development by 13 years , testicular volume below 4 mL by 14 years , or no menarche by 15 years or within 3 years of thelarche . Arrested pubertal progression also warrants assessment.

Constitutional Delay of Growth and Puberty (CDGP):

Accounts for >60% to 70% of delayed puberty cases, most common in boys. Normal variant with delayed skeletal maturation and family history of late puberty.

Hypergonadotropic Hypogonadism (Primary Gonadal Failure):

Characterized by elevated LH and FSH with low sex steroids.

Girls: Turner Syndrome (45,X) ; gonadal dysgenesis (streak ovaries).

Boys: Klinefelter Syndrome (47,XXY) (tall stature, small firm testes < 4 mL <4\text{ mL} < 4 mL , gynecomastia, elevated gonadotropins in late adolescence); bilateral cryptorchidism; post-chemotherapy/pelvic radiotherapy.

Hypogonadotropic Hypogonadism (Central Failure):

Characterized by low or inappropriately normal LH and FSH .

Kallmann Syndrome: Defective migration of GnRH neurons and olfactory placode; features delayed puberty accompanied by anosmia or hyposmia ( KAL1 or FGFR1 mutations).

Panhypopituitarism: Craniopharyngioma, midline CNS defects.

Functional Hypothalamic Amenorrhea: Chronic illness, anorexia nervosa, malnutrition, intense athletic training.

Inborn Errors of Metabolism: Acute Emergency Approach

Inborn errors of metabolism (IEMs) collectively affect 1 in 1,000 live births . In neonates, they present with non-specific, catastrophic deterioration after an initial symptom-free period following the introduction of milk feeds.

Clinical Presentation and Red Flags

The Clinical Paradigm: A full-term infant born after an uneventful pregnancy and delivery who is initially vigorous and feeds well for 24 to 48 hours , then rapidly develops:

  • Lethargy, somnolence, progressive coma
  • Intractable vomiting, poor feeding, dehydration
  • Tachypnea / hyperventilation (compensatory for metabolic acidosis)
  • Seizures, hypotonia, bicycling movements, or opisthotonos

Characteristic Odors:

  • Isovaleric Acidemia: "Sweaty feet" odor
  • Maple Syrup Urine Disease (MSUD): Sweet maple syrup / burnt sugar odor
  • Phenylketonuria (PKU): Mousy / musty odor
  • Glutaric Aciduria Type II: Sweaty feet / acrid odor
  • The Emergency Diagnostic "Metabolic Quartet"

Collect urgent samples before treatment where feasible, without delaying resuscitation . Four decisive laboratory parameters are:

Blood Gas: Identifies metabolic acidosis; calculate the serum anion gap ( [ Na + ] − [ Cl − + HCO 3 − ] > 16 mmol/L [\text{Na}^+] - [\text{Cl}^- + \text{HCO}_3^-] > 16\text{ mmol/L} [ Na + ] − [ Cl − + HCO 3 − ​ ] > 16 mmol/L ).

Blood Glucose: Identifies hypoglycemia (hypoketotic vs ketotic).

Serum Lactate: Identifies mitochondrial or pyruvate disorders, or secondary lactic acidosis in organic acidemias.

Plasma Ammonia: Identifies urea cycle disorders or organic acidemias. Normal neonatal ammonia is < 100 mcmol/L < 100\text{ mcmol/L} < 100 mcmol/L ; values > 150 – 200 mcmol/L > 150\text{--}200\text{ mcmol/L} > 150 – 200 mcmol/L are critically abnormal .

Critical immediate second-line samples (collect promptly; do not delay urgent treatment): Urine ketones, quantitative plasma amino acids, urine organic acids (GC-MS), and acylcarnitine profile on dried bloodspot.

  • Algorithmic Differential Diagnosis Based on the Metabolic Quartet [Acute neonatal metabolic collapse]
  • [Check blood gas, glucose/ketones, lactate and ammonia]
  • |
  • +------------------------------+------------------------------+
  • | | |
  • [Marked hyperammonaemia] [High-gap metabolic acidosis] [Hypoketotic hypoglycaemia]
  • [No primary acidosis / [Ketosis; ammonia may rise] [Ketones inappropriately low]
  • respiratory alkalosis] | |
  • | [Consider ORGANIC ACIDAEMIA] [Consider FATTY ACID
  • [Consider UREA CYCLE - MMA, propionic, isovaleric OXIDATION DEFECT]
  • DISORDER] - Urine organic acids - MCADD, VLCADD
  • OTC: high urine orotate - Acylcarnitine profile
  • CPS1, ASS, ASL defects - MCADD: elevated C8
  • | | |
  • +-------------------- [Urgent metabolic advice] --------------+
  • [Patterns guide tests; confirm the diagnosis]

Metabolic Entity Blood Gas / Anion Gap Plasma Ammonia Serum Glucose Key Diagnostic Findings

Urea Cycle Disorder (UCD) (e.g., OTC Deficiency) Normal pH or Respiratory Alkalosis (ammonia stimulates respiratory center) Markedly Elevated ( 300 to > 1 , 000 mcmol/L 300\text{ to }>1,000\text{ mcmol/L} 300 to > 1 , 000 mcmol/L ) Normal Low citrulline, markedly elevated urine orotic acid in OTC (X-linked)

Organic Acidemia (MMA, PA, Isovaleric Acidemia) Severe High Anion Gap Acidosis ( p H < 7.10 pH < 7.10 p H < 7.10 ) Moderately to Severely Elevated ( 150 – 500 mcmol/L 150\text{--}500\text{ mcmol/L} 150 – 500 mcmol/L ) Hypoglycemia or normal; Ketones strongly positive Elevated urine organic acids (methylmalonate, propionate, isovalerylglycine); pancytopenia

Fatty Acid Oxidation Defect (e.g., MCADD) Mild acidosis or normal Mildly elevated or normal Hypoketotic Hypoglycemia (inappropriately low ketones during hypoglycemia) Abnormal acylcarnitine profile (octanoylcarnitine C 8 C_8 C 8 ​ elevation in MCADD); hepatomegaly

Mitochondrial / PDH Deficiency Severe Lactic Acidosis ( L a c t a t e > 5 – 10 mmol/L Lactate > 5\text{--}10\text{ mmol/L} L a c t a t e > 5 – 10 mmol/L ) Normal or mildly elevated Normal or hypoglycemia High lactate-to-pyruvate ratio suggests respiratory-chain disease; normal/low ratio suggests PDH deficiency ; neurological dysfunction

Galactosemia (GALT deficiency) Normal or mild acidosis Normal Hypoglycemia Reducing substances in urine (positive Clinitest, negative glucose dipstick); cataracts, hepatomegaly, E. coli sepsis

Acute Emergency Resuscitation Protocol for Suspected IEM

Contact the metabolic centre urgently. The following anti-catabolic measures principally address intoxication-type crises; treatment must follow the biochemical findings and suspected diagnosis.

Halt Toxic Substrate Intake:

In hyperammonaemia or suspected organic acidaemia, temporarily stop protein-containing feeds . Reintroduce protein within 24–48 hours with the metabolic team; prolonged withdrawal promotes catabolism.

Reverse Catabolism and Promote Anabolism:

Start high-rate intravenous 10% Dextrose with electrolytes to achieve a Glucose Infusion Rate (GIR) of 8 to 10 mg/kg/min : GIR (mg/kg/min) = Glucose Concentration (%) × Infusion Rate (mL/h) 6 × Body Weight (kg) \text{GIR (mg/kg/min)} = \frac{\text{Glucose Concentration (\%)} \times \text{Infusion Rate (mL/h)}}{6 \times \text{Body Weight (kg)}} GIR (mg/kg/min) = 6 × Body Weight (kg) Glucose Concentration (%) × Infusion Rate (mL/h) ​

High GIR suppresses endogenous proteolysis and lipolysis. If hyperglycemia ( > 10 – 12 mmol/L >10\text{--}12\text{ mmol/L} > 10 – 12 mmol/L ) develops, do not decrease dextrose delivery ; instead, initiate a low-dose intravenous insulin infusion ( 0.02 – 0.05 U/kg/h 0.02\text{--}0.05\text{ U/kg/h} 0.02 – 0.05 U/kg/h ) to facilitate cellular glucose uptake and maximize anabolism.

Ammonia Detoxification (Scavenger Therapy):

For acute hyperammonemia, administer intravenous Sodium Benzoate and Sodium Phenylbutyrate :

Sodium benzoate conjugates with glycine to form hippurate, excreted by the kidneys.

Sodium phenylbutyrate / phenylacetate conjugates with glutamine to form phenylacetylglutamine, excreted in urine.

Both pathways bypass the defective urea cycle, excreting nitrogen waste.

Administer intravenous L-Arginine Hydrochloride (replenishes urea cycle intermediates in ASS/ASL deficiencies).

Cofactor Therapy:

Administer high-dose Hydroxocobalamin (Vitamin B 12 B_{12} B 12 ​ ) for suspected methylmalonic acidemia.

Administer Biotin for multiple carboxylase deficiency.

Administer L-Carnitine (50–100 mg/kg/day) to conjugate and eliminate toxic organic acyl groups (hold during acute phase of suspected long-chain FAODs due to arrhythmogenic acylcarnitine intermediates).

Extracorporeal Dialysis (CVVHD / Hemodialysis):

Mandatory first-line intervention if plasma ammonia is > 400 to 500 mcmol/L > 400\text{ to }500\text{ mcmol/L} > 400 to 500 mcmol/L , or if ammonia rises rapidly despite scavenger therapy, or in intractable life-threatening metabolic acidosis. Peritoneal dialysis is vastly inferior and inadequate for hyperammonemic coma.

Childhood Obesity

Definition : for ages 5–19 years, WHO BMI-for-age above +1 SD indicates overweight and above +2 SD indicates obesity; national programmes may use their own BMI centile charts.

Causes : most obesity is multifactorial (energy-dense diet, low activity, short sleep, screen time, family and socioeconomic factors). Suspect an endocrine cause when weight gain is accompanied by short stature or slowing height velocity (hypothyroidism, Cushing syndrome, growth hormone deficiency), whereas simple obesity usually accompanies normal or tall stature. Suspect a genetic cause with severe obesity before 5 years with hyperphagia (for example MC4R or leptin-pathway defects), developmental delay or dysmorphism, or Prader–Willi syndrome. Hypothalamic injury and drugs such as glucocorticoids and antipsychotics also cause weight gain.

Complications : hypertension, dyslipidaemia, insulin resistance with acanthosis nigricans, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea, idiopathic intracranial hypertension, slipped capital femoral epiphysis, Blount disease, polycystic ovary syndrome and psychosocial harm including bullying and depression.

Assessment : plot BMI, measure blood pressure with an appropriately sized cuff, examine for acanthosis nigricans, and screen for comorbidities such as glucose or HbA1c, lipids and liver enzymes according to local guidance.

Management : a non-stigmatising, family-based, multicomponent behavioural programme addressing diet, physical activity, sleep and screen time. For adolescents aged 12 years or older with obesity, EMA-authorised GLP-1 receptor agonists such as liraglutide or semaglutide may be added to diet and activity. Bariatric surgery is reserved for severe adolescent obesity in specialist centres.

Sources: WHO BMI-for-age (5–19 years) ; EMA Wegovy product information ; Endocrine Society paediatric obesity guideline .